Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903194 | 0.81 | CYP17A1 (0.50) | BRD4CYP1A2 | |
| SCHEMBL900109 | 0.78 | CYP17A1 (0.48) | BRD4AURKAJAK2RETABL1 | |
| SCHEMBL27151824 | 0.78 | PARP1 (0.42) | BRD4AURKAJAK2RPS6KA2ABL1 | |
| SCHEMBL20878376 | 0.76 | BRD4 (0.56) | BRD4AURKAJAK2RPS6KA2ABL1 | |
| SCHEMBL10140 | 0.75 | BRD4 (0.60) | BRD4AURKAJAK2RPS6KA2HTR2A | |
| SCHEMBL30663518 | 0.73 | BRD4 (1.00) | BRD4AURKAJAK2RPS6KA2HTR2A | |
| SCHEMBL29109173 | 0.73 | BRD4 (1.00) | BRD4AURKAJAK2RPS6KA2HTR2A | |
| SCHEMBL900129 | 0.72 | BRD4 (0.45) | BRD4AURKAJAK2RPS6KA2RET | |
| SCHEMBL29960424 | 0.72 | QPCT (0.51) | BRD4ABL1GSK3BCYP1A2CYP2E1 | |
| SCHEMBL27143869 | 0.72 | QPCT (0.51) | BRD4ABL1GSK3BCYP1A2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133160-B2 | Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2621913-B1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2621913-B1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2621913-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044537-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310393-A1 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS | CYP3A43, CYP2C18, CYP3A7 | BRD4 932/4885AURKA 2926/4885JAK2 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.